Welcome. Already a member? Click here to sign in.
New customer? Click here  to begin.
Free Shipping on orders over $39.00
Vet Approved PET Medications - for LESS...   @VetApprovedRx.com
Call Toll Free: 877.847.7389
Show me products used for:   Dogs   Cats    > All <
Search
Search  Go


 
Specials and Sales
Shop by condition
More options
Pet Filter
Show me products used for:
   Dogs
   Cats
   All



All Products US EPA And FDA Approved

We Ship USPS and FedEx.

Find Us On Facebook
Follow Us On Twitter

 

Shop


Etogesic,[Etodolac], a non-narcotic NSAID with anti-inflammatory, anti-pyretic, and analgesic activity. Indicated for the control of pain and inflammation associated with osteoarthritis in dogs.

Add this item to your cart:

Item# Size/Desc Qty Price
900090
150mg per tablet
$1.90
$1.40
Save $0.50!  
This item requires a RX
900091
150 mg 30 cnt bottle
$54.99
$42.25
Save $12.74!
Item qualifies for FREE SHIPPINGThis item requires a RX
900092
150 mg 90 cnt bottle
$157.99
$124.15
Save $33.84!
Item qualifies for FREE SHIPPINGThis item requires a RX
900093
300 mg per tablet
$2.25
$1.70
Save $0.55!
This item requires a RX
900094
300 mg 30 cnt bottle
$69.99
$50.40
Save $19.59!
Item qualifies for FREE SHIPPINGThis item requires a RX
900095
300 mg 90 cnt bottle
$189.99
$148.85
Save $41.14!
Item qualifies for FREE SHIPPINGThis item requires a RX

**Note: This product requires a veterinarian's prescription to purchase.At checkout you will need to provide your veterinarian's FAX or email address. We will then send him or her a prescription verification that he or she will need to sign and return before we can ship you this product.


Benefits:

Relieves pain and inflammation of osteoarthritis and other joint diseases, including hip dysplasia

Relieves joint stiffness

May also help reduce fevers


INDICATIONS:

EtoGesic Tablets are indicated for the control of pain and inflammation associated with osteoarthritis in dogs.

DOSAGE AND ADMINISTRATION:

Always provide Client Information sheet with prescription. Carefully consider the potential benefits and risks of ETOGESIC and other treatment options before deciding to use ETOGESIC. Use the lowest effective dose for the shortest duration consistent with individual treatment response.

The recommended dose of ETOGESIC Tablets is 4.5 to 6.8 mg/lb body weight 10 to 15 mg/kg administered once daily. Due to tablet sizes and scoring, dogs weighing less than 11 lb 5 kg cannot be accurately dosed. The effective dose and duration should be based on clinical judgment of disease condition and patient tolerance of drug treatment. The initial dose level should be adjusted until a satisfactory clinical response is obtained, but should not exceed 15 mg/kg once daily.

CONTRAINDICATIONS:

EtoGesic Tablets are contraindicated in animals previously found to be hypersensitive to etodolac.

WARNINGS:

Not for human use. Keep out of reach of children. Consult a physician in cases of accidental ingestion by humans. Do not use in cats. For use in dogs only.

All dogs should undergo a thorough history and physical examination before initiation of NSAID therapy. Appropriate laboratory tests to establish hematological and serum biochemical baseline data prior to, and periodically during, administration of any NSAID is recommended. Owners should be advised to observe for signs of potential drug toxicity see Information for Dog Owners, Animal Safety, and Adverse Reactions and be given a client information sheet about ETOGESIC.

For technical assistance or to report a suspected adverse reaction, call 1-800-533-8536.

PRECAUTIONS:

The safe use of ETOGESIC Tablets in dogs less than 12 months of age, pregnant, breeding or lactating dogs has not been established. Owners should be advised to observe for signs of potential drug reactions. If additional pain medication is warranted after administration of the daily dose of ETOGESIC, alternative analgesia should be considered. The use of another NSAID is not recommended.

As a class, cyclooxygenase inhibitory NSAIDs may be associated with gastrointestinal, renal, and hepatic toxicity. Sensitivity to drug-associated adverse effects varies with the individual patient. Dogs that have experienced adverse reactions from one NSAID may experience adverse reactions from other NSAIDs. Dogs at greatest risk for adverse events are those that are dehydrated, on concomitant diuretic therapy, or those with renal, cardiovascular, and/or hepatic dysfunction. Concurrent administration of potentially nephrotoxic drugs should be carefully approached and monitored. NSAIDs may inhibit the prostaglandins that maintain normal homeostatic function. Such anti-prostaglandin effects may result in clinically significant disease in patients with underlying or pre-existing disease that has not been previously diagnosed. Since NSAIDs possess the potential to induce gastrointestinal ulceration and/or gastrointestinal perforation, concomitant use of ETOGESIC with other anti-inflammatory drugs, such as other NSAIDs or corticosteroids, should be avoided.

The use of concomitantly protein-bound drugs with ETOGESIC has not been studied in dogs. Commonly used protein-bound drugs include cardiac, anticonvulsant and behavioral medications. The influence of concomitant drugs that may inhibit metabolism of ETOGESIC has not been evaluated. Drug compatibility should be monitored in patients requiring adjunctive therapy. Consider appropriate washout times when switching from one NSAID to another or when switching from corticosteroid use to NSAID use.

Treatment with ETOGESIC Tablets should be terminated if signs such as inappetence, emesis, fecal abnormalities, or anemia are observed. Dogs treated with non-steroidal anti-inflammatory drugs on a continuing basis, including etodolac, should be evaluated periodically to ensure that the drug is still necessary and well tolerated.

ETOGESIC Tablets, as with other non-steroidal anti-inflammatory drugs, may exacerbate clinical signs in dogs with pre-existing or occult gastrointestinal, hepatic or cardiovascular abnormalities, blood dyscrasias, or bleeding disorders.

ADVERSE REACTIONS:

In a placebo-controlled field study with ETOGESIC Tablets involving 116 dogs, where treatment was administered for 8 days, the following adverse reactions were noted:

Adverse Reaction

EtoGesic Tablets
% of Dogs

Placebo
% of Dogs

vomiting

4.3%

1.7%

regurgitation

0.9%

2.6%

lethargy

3.4%

2.6%

diarrhea/loose stool

2.6%

1.7%

hypoproteinemia

2.6%

0

urticaria

0.9%

0

behavioral change, urinating in house

0.9%

0

inappetence

0.9%

1.7%

Following completion of the field study, 92 dogs continued to receive etodolac tablets. One dog developed diarrhea following 2-1/2 weeks of treatment. Etodolac was discontinued until resolution of clinical signs was observed. When treatment was resumed, the diarrhea returned within 24 hours. One dog experienced vomiting which was attributed to treatment, and etodolac was discontinued.

Hypoproteinemia was identified in one dog following 11 months of etodolac therapy. Treatment was discontinued, and serum protein levels subsequently returned to normal.

ETOGESIC Tablets Post-Approval Experience:

As with other drugs in the NSAID class, adverse responses to ETOGESIC Tablets may occur. The adverse drug reactions listed below are based on voluntary post-approval reporting for ETOGESIC Tablets. The categories of adverse reaction reports are listed below in decreasing order of frequency by body system.

Gastrointestinal: Vomiting, diarrhea, inappetence, gastroenteritis, gastrointestinal bleeding, melena, gastrointestinal ulceration, hypoproteinemia, elevated pancreatic enzymes.

Hepatic: Abnormal liver function tests, elevated hepatic enzymes, icterus, acute hepatitis.

Hematological: Anemia, hemolytic anemia, thrombocytopenia, prolonged bleeding time.

Neurological/Behavioral/Special Senses: Ataxia, paresis, aggression, sedation, hyperactivity, disorientation, hyperesthesia, seizures, vestibular signs, keratoconjunctivitis sicca.

Renal: Polydipsia, polyuria, urinary incontinence, azotemia, acute renal failure, proteinuria, hematuria.

Dermatological/Immunological: Pruritus, dermatitis, edema, alopecia, urticaria.

Cardiovascular/Respiratory: Tachycardia, dyspnea.

In rare situations, death has been reported as an outcome of some of the adverse reactions listed above.

For technical assistance, to report a suspected adverse reaction, or obtain a Material Safety Data Sheet, call 1-800-533-8536.

INFORMATION FOR DOG OWNERS:

ETOGESIC, like other drugs of its class, is not free from adverse reactions. Owners should be advised of the potential for adverse reactions and be informed of the clinical signs associated with drug intolerance. Adverse reactions may include decreased appetite, vomiting, diarrhea, dark or tarry stools, increased water consumption, increased urination, pale gums due to anemia, yellowing of gums, skin or white of the eye due to jaundice, lethargy, incoordination, seizure, or behavioral changes. Serious adverse reactions associated with this drug class can occur without warning and in rare situations result in death see Adverse Reactions. Owners should be advised to discontinue ETOGESIC therapy and contact their veterinarian immediately if signs of intolerance are observed. The vast majority of patients with drug related adverse reactions have recovered when the signs are recognized, the drug is withdrawn, and veterinary care, if appropriate, is initiated. Owners should be advised of the importance of periodic follow-up for all dogs receiving a continuing regimen of any NSAID.